Measurable residual disease in hematopoietic stem cell transplantation-eligible patients with acute myeloid leukemia: clinical significance and promising therapeutic strategies

References

• Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447.
   PubMed Web of Science ®Google Scholar
• Honda S, Koreth J, Djulbegovic BJ, et al. Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete remission: systematic review and meta-analysis of prospective clinical trials. Jama. 2009;301(22):2349–2361.
   PubMed Web of Science ®Google Scholar
• Cornelissen JJ, Gratwohl A, Schlenk RF, et al. The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nat Rev Clin Oncol. 2012;9(10):579–590.
   PubMed Web of Science ®Google Scholar
• Cornelissen JJ, Blaise D. Hematopoietic stem cell transplantation for patients with AML in first complete remission. Blood. 2016;127(1):62–70.
   PubMed Web of Science ®Google Scholar
• Verneris MR, Burke MJ. Novel approaches to prevent leukemia relapse following allogeneic hematopoietic cell transplantation. Curr Hematol Malig Rep. 2010;5(3):157–162.
   PubMed Web of Science ®Google Scholar
• Kassim AA, Savani BN. Hematopoietic stem cell transplantation for acute myeloid leukemia: a review. Hematol Oncol Stem Cell Ther. 2017;10(4):245–251.
   PubMedGoogle Scholar
• Schuurhuis GJ, Heuser M, Freeman S, et al. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2018;131(12):1275–1291.
   PubMed Web of Science ®Google Scholar
• Ossenkoppele G, Schuurhuis GJ. MRD in AML: time for redefinition of CR? Blood. 2013;121(12):2166–2168.
   PubMed Web of Science ®Google Scholar
• Nagler A, Baron F, Labopin M, et al. Measurable residual disease (MRD) testing for acute leukemia in EBMT transplant centers: a survey on behalf of the ALWP of the EBMT. Bone Marrow Transplant 2020; [cited 2020 Sep 22].
   Google Scholar
• Elorza I, Palacio C, Dapena JL, et al. Relationship between minimal residual disease measured by multiparametric flow cytometry prior to allogeneic hematopoietic stem cell transplantation and outcome in children with acute lymphoblastic leukemia. Haematologica. 2010;95(6):936–941.
   PubMed Web of Science ®Google Scholar
• Knechtli CJ, Goulden NJ, Hancock JP, et al. Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia. Blood. 1998;92(11):4072–4079.
   PubMed Web of Science ®Google Scholar
• Gökbuget N, Dombret H, Bonifacio M, et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2018;131(14):1522–1531.
   PubMed Web of Science ®Google Scholar
• Buccisano F, Maurillo L, Del Principe MI, et al. Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. Blood. 2012;119(2):332–341.
   PubMed Web of Science ®Google Scholar
• Venditti A, Buccisano F, Del Poeta G, et al. Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. Blood. 2000;96(12):3948–3952.
   PubMed Web of Science ®Google Scholar
• Balsat M, Renneville A, Thomas X, et al. Postinduction minimal residual disease predicts outcome and benefit from allogeneic stem cell transplantation in acute myeloid leukemia with NPM1 mutation: a study by the acute leukemia French association group. J Clin Oncol. 2017;35(2):185–193.
   PubMed Web of Science ®Google Scholar
• Terwijn M, van Putten WL, Kelder A, et al. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. J Clin Oncol. 2013;31(31):3889–3897.
   PubMed Web of Science ®Google Scholar
• Walter RB, Gooley TA, Wood BL, et al. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. J Clin Oncol. 2011;29(9):1190–1197.
   PubMed Web of Science ®Google Scholar
• Norkin M, Katragadda L, Zou F, et al. Minimal residual disease by either flow cytometry or cytogenetics prior to an allogeneic hematopoietic stem cell transplant is associated with poor outcome in acute myeloid leukemia. Blood Cancer J. 2017;7(12):634.
   PubMedGoogle Scholar
• Maurillo L, Buccisano F, Del Principe MI, et al. Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia. J Clin Oncol. 2008;26(30):4944–4951.
   PubMed Web of Science ®Google Scholar
• Anthias C, Dignan FL, Morilla R, et al. Pre-transplant MRD predicts outcome following reduced-intensity and myeloablative allogeneic hemopoietic SCT in AML. Bone Marrow Transplant. 2014;49(5):679–683.
   PubMed Web of Science ®Google Scholar
• Oran B, Jorgensen JL, Marin D, et al. Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia. Haematologica. 2017;102(1):110–117.
   PubMed Web of Science ®Google Scholar
• Walter RB, Gyurkocza B, Storer BE, et al. Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation. Leukemia. 2015;29(1):137–144.
   PubMed Web of Science ®Google Scholar
• Araki D, Wood BL, Othus M, et al. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: time to move toward a minimal residual disease-based definition of complete remission? J Clin Oncol. 2016;34(4):329–336.
   PubMed Web of Science ®Google Scholar
• Ravandi F, Walter RB, Freeman SD. Evaluating measurable residual disease in acute myeloid leukemia. Blood Adv. 2018;2(11):1356–1366.
   PubMed Web of Science ®Google Scholar
• Bastos-Oreiro M, Perez-Corral A, Martínez-Laperche C, et al. Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acute myeloid leukemia before and after allogeneic hemopoietic stem cell transplantation. Eur J Haematol. 2014;93(3):239–246.
   PubMed Web of Science ®Google Scholar
• Bradbury C, Houlton AE, Akiki S, et al. Prognostic value of monitoring a candidate immunophenotypic leukaemic stem/progenitor cell population in patients allografted for acute myeloid leukaemia. Leukemia. 2015;29(4):988–991.
   PubMed Web of Science ®Google Scholar
• Grubovikj RM, Alavi A, Koppel A, et al. Minimal residual disease as a predictive factor for relapse after allogeneic hematopoietic stem cell transplant in adult patients with acute myeloid leukemia in first and second complete remission. Cancers. 2012;4(2):601–617.
   PubMedGoogle Scholar
• Gyurkocza B, Storb R, Storer BE, et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. J Clin Oncol. 2010;28(17):2859–2867.
   PubMed Web of Science ®Google Scholar
• Jacobsohn DA, Tse WT, Chaleff S, et al. High WT1 gene expression before haematopoietic stem cell transplant in children with acute myeloid leukaemia predicts poor event-free survival. Br J Haematol. 2009;146(6):669–674.
   PubMed Web of Science ®Google Scholar
• Kayser S, Benner A, Thiede C, et al. Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia. Blood Cancer J. 2016;6(7):e449.
   PubMed Web of Science ®Google Scholar
• Kebriaei P, Kline J, Stock W, et al. Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes. Bone Marrow Transplant. 2005;35(10):965–970.
   PubMed Web of Science ®Google Scholar
• Kern W, Voskova D, Schoch C, et al. Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia. Blood. 2004;104(10):3078–3085.
   PubMed Web of Science ®Google Scholar
• Laane E, Derolf AR, Björklund E, et al. The effect of allogeneic stem cell transplantation on outcome in younger acute myeloid leukemia patients with minimal residual disease detected by flow cytometry at the end of post-remission chemotherapy. Haematologica. 2006;91(6):833–836.
   PubMed Web of Science ®Google Scholar
• Leung W, Campana D, Yang J, et al. High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia. Blood. 2011;118(2):223–230.
   PubMed Web of Science ®Google Scholar
• Leung W, Pui C-H, Coustan-Smith E, et al. Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia. Blood. 2012;120(2):468–472.
   PubMed Web of Science ®Google Scholar
• Oran B, Popat U, Rondon G, et al. Significance of persistent cytogenetic abnormalities on myeloablative allogeneic stem cell transplantation in first complete remission. Biol Blood Marrow Transplant. 2013;19(2):214–220.
   PubMed Web of Science ®Google Scholar
• Pozzi S, Geroldi S, Tedone E, et al. Leukaemia relapse after allogeneic transplants for acute myeloid leukaemia: predictive role of WT1 expression. Br J Haematol. 2013;160(4):503–509.
   PubMed Web of Science ®Google Scholar
• Rossi G, Minervini MM, Melillo L, et al. Predictive role of minimal residual disease and log clearance in acute myeloid leukemia: a comparison between multiparameter flow cytometry and Wilm’s tumor 1 levels. Ann Hematol. 2014;93:1149–1157.
   PubMed Web of Science ®Google Scholar
• Rossi G, Carella AM, Minervini MM, et al. Optimal time-points for minimal residual disease monitoring change on the basis of the method used in patients with acute myeloid leukemia who underwent allogeneic stem cell transplantation: a comparison between multiparameter flow cytometry and Wilms’ tumor 1 expression. Leuk Res. 2015;39(2):138–143.
   PubMed Web of Science ®Google Scholar
• Ustun C, Wiseman AC, Defor TE, et al. Achieving stringent CR is essential before reduced-intensity conditioning allogeneic hematopoietic cell transplantation in AML. Bone Marrow Transplant. 2013;48(11):1415–1420.
   PubMed Web of Science ®Google Scholar
• Válková V, Polák J, Marková M, et al. Minimal residual disease detectable by quantitative assessment of WT1 gene before allogeneic stem cell transplantation in patients in first remission of acute myeloid leukemia has an impact on their future prognosis. Clin Transplant. 2013;27(1):E21–9.
   PubMed Web of Science ®Google Scholar
• Walter RB, Buckley SA, Pagel JM, et al. Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. Blood. 2013;122(10):1813–1821.
   PubMed Web of Science ®Google Scholar
• Zhao X-S, Jin S, Zhu H-H, et al. Wilms’ tumor gene 1 expression: an independent acute leukemia prognostic indicator following allogeneic hematopoietic SCT. Bone Marrow Transplant. 2012;47(4):499–507.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Othus M, Araki D, et al. Pre- and post-transplant quantification of measurable (‘minimal’) residual disease via multiparameter flow cytometry in adult acute myeloid leukemia. Leukemia. 2016;30(7):1456–1464.
   PubMed Web of Science ®Google Scholar
• Buckley SA, Wood BL, Othus M, et al. Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis. Haematologica. 2017;102(5):865–873.
   PubMed Web of Science ®Google Scholar
• Short NJ, Ravandi F. How close are we to incorporating measurable residual disease into clinical practice for acute myeloid leukemia? Haematologica. 2019;104(8):1532–1541.
   PubMed Web of Science ®Google Scholar
• Liu Yin JA, Grimwade D. Minimal residual disease evaluation in acute myeloid leukaemia. Lancet. 2002;360(9327):160–162.
   PubMed Web of Science ®Google Scholar
• Kumar CC. Genetic abnormalities and challenges in the treatment of acute myeloid Leukemia. Genes Cancer. 2011;2(2):95–107.
   PubMedGoogle Scholar
• Döhner H, Stilgenbauer S, Fischer K, et al. Diagnosis and monitoring of chromosome aberrations in hematological malignancies by fluorescence in situ hybridization. Stem Cells. 1995;13(Suppl 3):76–82.
   PubMedGoogle Scholar
• Campana D, Coustan-Smith E. Detection of minimal residual disease in acute leukemia by flow cytometry. Cytometry. 1999;38(4):139–152.
   PubMedGoogle Scholar
• Campana D, Pui C. Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance [see comments. Blood. 1995;85(6):1416–1434.
   PubMed Web of Science ®Google Scholar
• San Miguel JF, Martínez A, Macedo A, et al. Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients. Blood. 1997;90(6):2465–2470.
   PubMed Web of Science ®Google Scholar
• Kern W, Danhauser-Riedl S, Ratei R, et al. Detection of minimal residual disease in unselected patients with acute myeloid leukemia using multiparameter flow cytometry to define leukemia-associated immunophenotypes and determine their frequencies in normal bone marrow. Haematologica. 2003;88:646–653.
   PubMed Web of Science ®Google Scholar
• Voso MT, Ottone T, Lavorgna S, et al. MRD in AML: the role of new techniques. Front Oncol. 2019;9:e00655.
   PubMed Web of Science ®Google Scholar
• Craddock C, Quek L, Goardon N, et al. Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia. Leukemia. 2013;27(5):1028–1036.
   PubMed Web of Science ®Google Scholar
• Zhu HH, Zhang XH, Qin YZ, et al. MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: Results from the AML05 multicenter trial. Blood. 2013;121(20):4056–4062.
   PubMed Web of Science ®Google Scholar
• Cilloni D, Gottardi E, De Micheli D, et al. Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia. 2002;16(10):2115–2121.
   PubMed Web of Science ®Google Scholar
• Garg M, Moore H, Tobal K, et al. Prognostic significance of quantitative analysis of WT1 gene transcripts by competitive reverse transcription polymerase chain reaction in acute leukaemia. Br J Haematol. 2003;123(1):49–59.
   PubMed Web of Science ®Google Scholar
• Weisser M, Kern W, Rauhut S, et al. Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia. Leukemia. 2005;19(8):1416–1423.
   PubMed Web of Science ®Google Scholar
• Rossi G, Carella AM, Minervini MM, et al. Minimal residual disease after allogeneic stem cell transplant: a comparison among multiparametric flow cytometry, Wilms tumor 1 expression and chimerism status (Complete chimerism versus Low Level Mixed Chimerism) in acute leukemia. Leuk Lymphoma. 2013;54(12):2660–2666.
   PubMed Web of Science ®Google Scholar
• Lange T, Hubmann M, Burkhardt R, et al. Monitoring of WT1 expression in PB and CD34+ donor chimerism of BM predicts early relapse in AML and MDS patients after hematopoietic cell transplantation with reduced-intensity conditioning. Leukemia. 2011;25(3):498–505.
   PubMed Web of Science ®Google Scholar
• Dominietto A, Pozzi S, Miglino M, et al. Donor lymphocyte infusions for the treatment of minimal residual disease in acute leukemia. Blood. 2007;109(11):5063–5064.
   PubMed Web of Science ®Google Scholar
• Elmaagacli AH, Beelen DW, Trenschel R, et al. The detection of wt-1 transcripts is not associated with an increased leukemic relapse rate in patients with acute leukemia after allogeneic bone marrow or peripheral blood stem cell transplantation. Bone Marrow Transplant. 2000;25(1):91–96.
   PubMed Web of Science ®Google Scholar
• Miyazaki T, Fujita H, Fujimaki K, et al. Clinical significance of minimal residual disease detected by multidimensional flow cytometry: serial monitoring after allogeneic stem cell transplantation for acute leukemia. Leuk Res. 2012;36(8):998–1003.
   PubMed Web of Science ®Google Scholar
• Ogawa H, Tamaki H, Ikegame K, et al. The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Blood. 2003;101(5):1698–1704.
   PubMed Web of Science ®Google Scholar
• Kwon M, Martínez-Laperche C, Infante M, et al. Evaluation of minimal residual disease by real-time quantitative PCR of Wilms' tumor 1 expression in patients with acute myelogenous leukemia after allogeneic stem cell transplantation: correlation with flow cytometry and chimerism. Biol Blood Marrow Transplant. 2012;18(8):1235–1242.
   PubMed Web of Science ®Google Scholar
• Candoni A, Tiribelli M, Toffoletti E, et al. Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia. Eur J Haematol. 2009;82(1):61–68.
   PubMed Web of Science ®Google Scholar
• Candoni A, Toffoletti E, Gallina R, et al. Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leukemia. Clin Transplant. 2011;25(2):308–316.
   PubMed Web of Science ®Google Scholar
• Bacher U, Zander AR, Haferlach T, et al. Minimal residual disease diagnostics in myeloid malignancies in the post transplant period. Bone Marrow Transplant. 2008;42(3):145–157.
   PubMed Web of Science ®Google Scholar
• Hosen N, Sonoda Y, Oji Y, et al. Very low frequencies of human normal CD34+ haematopoietic progenitor cells express the Wilms’ tumour gene WT1 at levels similar to those in leukaemia cells. Br J Haematol. 2002;116(2):409–420.
   PubMed Web of Science ®Google Scholar
• Levine RL, Valk PJM. Next-generation sequencing in the diagnosis and minimal residual disease assessment of acute myeloid leukemia. Haematologica. 2019;104(5):868–871.
   PubMed Web of Science ®Google Scholar
• Kröger N, Miyamura K, Bishop MR. Minimal residual disease following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2011;17(1 Suppl):S94–S100.
   PubMed Web of Science ®Google Scholar
• Bader P, Kreyenberg H, Hoelle W, et al. Increasing mixed chimerism defines a high-risk group of childhood acute myelogenous leukemia patients after allogeneic stem cell transplantation where pre-emptive immunotherapy may be effective. Bone Marrow Transplant. 2004;33(8):815–821.
   PubMed Web of Science ®Google Scholar
• Barrios M, Jiménez-Velasco A, Román-Gómez J, et al. Chimerism status is a useful predictor of relapse after allogeneic stem cell transplantation for acute leukemia. Haematologica. 2003;88:801–810.
   PubMed Web of Science ®Google Scholar
• Bornhäuser M, Oelschlaegel U, Platzbecker U, et al. Monitoring of donor chimerism in sorted CD34+ peripheral blood cells allows the sensitive detection of imminent relapse after allogeneic stem cell transplantation. Haematologica. 2009;94(11):1613–1617.
   PubMed Web of Science ®Google Scholar
• Choi SJ, Lee KH, Lee JH, et al. Prognostic value of hematopoietic chimerism in patients with acute leukemia after allogeneic bone marrow transplantation: a prospective study. Bone Marrow Transplant. 2000;26(3):327–332.
   PubMed Web of Science ®Google Scholar
• Díez-Campelo M, Pérez-Simón JA, Pérez J, et al. Minimal residual disease monitoring after allogeneic transplantation may help to individualize post-transplant therapeutic strategies in acute myeloid malignancies. Am J Hematol. 2009;84(3):149–152.
   PubMed Web of Science ®Google Scholar
• Huisman C, de Weger RA, de Vries L, et al. Chimerism analysis within 6 months of allogeneic stem cell transplantation predicts relapse in acute myeloid leukemia. Bone Marrow Transplant. 2007;39(5):285–291.
   PubMed Web of Science ®Google Scholar
• Lamba R, Abella E, Kukuruga D, et al. Mixed hematopoietic chimerism at day 90 following allogenic myeloablative stem cell transplantation is a predictor of relapse and survival. Leukemia. 2004;18(10):1681–1686.
   PubMed Web of Science ®Google Scholar
• Pérez-Simón JA, Caballero D, Diez-Campelo M, et al. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation. Leukemia. 2002;16(8):1423–1431.
   PubMed Web of Science ®Google Scholar
• Tang X, Alatrash G, Ning J, et al. Increasing chimerism after allogeneic stem cell transplantation is associated with longer survival time. Biol Blood Marrow Transplant. 2014;20(8):1139–1144.
   PubMed Web of Science ®Google Scholar
• Zeiser R, Spyridonidis A, Wäsch R, et al. Evaluation of immunomodulatory treatment based on conventional and lineage-specific chimerism analysis in patients with myeloid malignancies after myeloablative allogeneic hematopoietic cell transplantation. Leukemia. 2005;19(5):814–821.
   PubMed Web of Science ®Google Scholar
• Jółkowska J, Pieczonka A, Strabel T, et al. Hematopoietic chimerism after allogeneic stem cell transplantation: A comparison of quantitative analysis by automated DNA sizing and fluorescent in situ hybridization. BMC Blood Disord. 2005;5:1.
   PubMedGoogle Scholar
• Bader P, Niethammer D, Willasch A, et al. How and when should we monitor chimerism after allogeneic stem cell transplantation? Bone Marrow Transplant. 2005;35(2):107–119.
   PubMed Web of Science ®Google Scholar
• Rautenberg C, Germing U, Haas R, et al. Relapse of acute myeloid leukemia after allogeneic stem cell transplantation: Prevention, detection, and treatment. Int J Mol Sci. 2019;20(1):228.
   Web of Science ®Google Scholar
• Buccisano F, Maurillo L, Gattei V, et al. The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia. Leukemia. 2006;20(10):1783–1789.
   PubMed Web of Science ®Google Scholar
• Venditti A, Maurillo L, Buccisano F, et al. Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation. Leukemia. 2003;17(11):2178–2182.
   PubMed Web of Science ®Google Scholar
• Osborne D, Frost L, Tobal K, et al. Elevated levels of WT1 transcripts in bone marrow harvests are associated with a high relapse risk in patients autografted for acute myeloid leukemia. Bone Marrow Transplant. 2005;36(1):67–70.
   PubMed Web of Science ®Google Scholar
• Buckley SA, Appelbaum FR, Walter RB. Prognostic and therapeutic implications of minimal residual disease at the time of transplantation in acute leukemia. Bone Marrow Transplant. 2013;48(5):630–641.
   PubMed Web of Science ®Google Scholar
• Rein LA, Sung AD, Rizzieri DA. New approaches to manipulate minimal residual disease after allogeneic stem cell transplantation. Int J Hematol Oncol. 2013;2(1):39–48.
   Google Scholar
• Venditti A, Piciocchi A, Candoni A, et al. Gimema AML1310 trial of risk-adapted, mrd-directed therapy for young adults with newly diagnosed acute myeloid Leukemia. Blood. 2019;134(12):935–945. blood.
   PubMedGoogle Scholar
• Freeman SD, Hills RK, Virgo P, et al. Measurable residual disease at induction redefines partial response in acute myeloid leukemia and stratifies outcomes in patients at standard risk without NPM1 mutations. J Clin Oncol. 2018;36(15):1486–1497.
   PubMed Web of Science ®Google Scholar
• Venditti A, Peter Gale R, Buccisano F, et al. Should persons with acute myeloid leukemia (AML) in 1st histological complete remission who are measurable residual disease (MRD) test positive receive an allotransplant? Leukemia. 2020;34(4):963–965.
   PubMed Web of Science ®Google Scholar
• Topp MS, Kufer P, Gökbuget N, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol. 2011;29(18):2493–2498.
   PubMed Web of Science ®Google Scholar
• Appelbaum J, Loeb A, Gardner K, et al. Additional cytotoxic chemotherapy is unlikely to eliminate measurable residual Acute Myeloid Leukemia (AML). Blood. 2019;134(Supplement_1):260–260.
   Google Scholar
• Pollyea DA, Gutman JA, Gore L, et al. Targeting acute myeloid leukemia stem cells: a review and principles for the development of clinical trials. Haematologica. 2014;99(8):1277–1284.
   PubMed Web of Science ®Google Scholar
• Ball B, Stein EM. Which are the most promising targets for minimal residual disease-directed therapy in acute myeloid leukemia prior to allogeneic stem cell transplant?. Haematologica. 2019;104(8):1521–1531.
   PubMed Web of Science ®Google Scholar
• Stone RM, Collins R, Tallman MS, et al. Effect of cytarabine/anthracycline/crenolanib induction on minimal residual disease (MRD) in newly diagnosed FLT3 mutant AML. J Clin Oncol. 2017;35(15_suppl):7016–7016.
   Google Scholar
• Stein EM, DiNardo CD, Fathi AT, et al. Ivosidenib or enasidenib combined with induction and consolidation chemotherapy in patients with newly diagnosed AML with an IDH1 or IDH2 mutation is safe, effective, and leads to MRD-negative complete remissions. Blood. 2018;132(Supplement 1):560–560.
   Web of Science ®Google Scholar
• DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133(1):7–17.
   PubMed Web of Science ®Google Scholar
• Assi R, Kantarjian HM, Daver NG, et al. Results of a phase 2, open-label study of idarubicin (I), Cytarabine (A) and Nivolumab (Nivo) in patients with newly diagnosed Acute Myeloid Leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood. 2018;132(Supplement 1):905–905.
   Web of Science ®Google Scholar
• Hourigan CS, Dillon LW, Gui G, et al. Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease. J Clin Oncol. 2020;38(12):1273–1283.
   PubMed Web of Science ®Google Scholar
• Yan CH, Liu DH, Liu KY, et al. Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Blood. 2012;119(14):3256–3262.
   PubMed Web of Science ®Google Scholar
• Di Grazia C, Pozzi S, Geroldi S, et al. Wilms tumor 1 expression and pre-emptive immunotherapy in patients with acute myeloid leukemia undergoing an allogeneic hemopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2016;22(7):1242–1246.
   PubMed Web of Science ®Google Scholar
• Spyridonidis A. How I treat measurable (minimal) residual disease in acute leukemia after allogeneic hematopoietic cell transplantation. Blood. 2020;135(19):1639–1649.
   PubMed Web of Science ®Google Scholar
• Platzbecker U, Wermke M, Radke J, et al. Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. Leukemia. 2012;26(3):381–389.
   PubMed Web of Science ®Google Scholar
• Platzbecker U, Middeke JM, Sockel K, et al. Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial. Lancet Oncol. 2018;19(12):1668–1679.
   PubMed Web of Science ®Google Scholar
• Schroeder T, Rachlis E, Bug G, et al. Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell transplantation with azacitidine and donor lymphocyte infusions-a retrospective multicenter analysis from the german cooperative transplant study group. Biol Blood Marrow Transplant. 2015;21(4):653–660.
   PubMed Web of Science ®Google Scholar